Idexx Laboratories price target raised to $722 from $626 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Idexx Laboratories (IDXX) to $722 from $626 and keeps an Overweight rating on the shares. Following the Q2 results, what “stood out to us” was accelerating consumables growth globally as well as an expanding inVue installed base, the analyst tells investors. An expanding installed base and share gains set the stage for accelerating growth when the market normalizes, the analyst contends.